SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
SAGE Therapeutics is a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABA A and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders.
Recent Articles
- Umicore's Outstanding Performance Highlights for H1 2025
- Atos Group Reports Strategic Progress and Financial Outlook
- Understanding Brunel's Q2 and H1 2025 Performance Insights
- Nyrstar NV Announces Change of Office Address Effective Immediately
- Renault Group's Strategic Growth in India and Leadership Changes
- BW Energy's Stellar Performance in First Half of 2025
- BW Energy Celebrates Remarkable Growth and Performance in 2025
- Renault Group's Enhanced Focus on India's Automotive Market Growth
- Nyrstar NV Announces New Registered Office Location in Belgium
- Innovative Robotaxi Growth and Success in Recent Financials
- Apple's Recent Earnings Show Strong Growth, Future Prospects
- WeRide Reports Major Growth in Q2, Robotaxi Revenue Soars
- WeRide Announces Impressive Growth in Q2 2025 Financials
- GOAT Network Unveils Innovative BitVM2 Testnet for Instant Withdrawals
- Shareholders Push for Accountability at Lincoln Gold Mining
- Fosun Tourism Group Secures Major Loan for Global Growth Strategies
- Mark Cuban Critiques Patent Tax Plan as Harmful to Innovation
- Fosun Tourism Group Secures €800 Million Loan from Top Banks
- CleaDeep Launches Innovative Brand Arspura for Healthier Homes
- Tim Cook Highlights Apple's Commitment to AI Through M&A
- Mission Valley Bancorp Shows Mixed Results in Financials
- Goldnx Expands AI Trading Infrastructure for Canadian Traders
- Peter Schiff Critiques Federal Reserve's Inflation Oversight
- SIEW 2025: Register Now for a Sustainable Energy Future
- SIEW 2025: An Invitation to Shape the Future of Energy
- Mission Valley Bancorp's Q2 Performance: Insights and Growth
- GenScript Biotech Achieves Prestigious AA ESG Rating Upgrade
- Predictions for India's Economic Growth Through 2035
- Alto Neuroscience Investors Urged to Take Action Before Deadline
- Propel Fuels Achieves Major Legal Victory Against Phillips 66
- 3D Systems Corporation's Class Action Lawsuit Overview
- Ningjin County Thrives in Global Fitness Equipment Market
- India's Economic Growth: Trends and Predictions to 2035
- Stallion Uranium Enhances Technology Licensing Agreement for Growth
- Kent Family Office Expands Investment in Turkish Pharma Sector
- APhA Voices Strong Concerns Over ACIP's Recent Decisions
- Guidance for Centene Corporation Investors Amid Class Action
- General Dynamics Expands Naval Capabilities with New Contract
- Legal Insights on Recent Corporate Transactions for Shareholders
- Zenara Pharma’s Groundbreaking Generic Approval for Sertraline
- General Dynamics Bath Iron Works Secures Navy Destroyer Contract
- DermRays Unveils Revolutionary Men's Hair Removal Device
- DermRays Unveils Innovative Hair Removal Device for Men
- Phosphorous Trichloride Market Projected to Hit $3.46 Billion
- Revolutionizing Automotive Sales with Voice-First AI Solutions
- Gary Kooner Sets New Standards as a 2025 Emerging Leader
- HCM III Acquisition Corp. Launches $220 Million IPO with Focus on Fintech
- Exploring the Future of Phosphorous Trichloride Market Dynamics
- XPENG Achieves Record Deliveries and Expands Market Reach
- The Ether Machine Commemorates Ethereum's Milestone with ETH Buy